Nigeria Collects the Samples. Someone Else Sequences Them.

There is a sentence that appears in African genomics papers so routinely that it stops registering. Samples were collected at the study site. DNA was extracted locally. Aliquots were shipped to a partner institution abroad for whole genome sequencing.

Consider one recent example. In an Alzheimer's genetics study running across West Africa, blood was collected at sites across the region and transported to a coordinating centre in Ibadan, where DNA extraction, plasma isolation and long-term storage took place. Aliquots of that DNA were then shipped to a university institute in Miami for whole genome sequencing and biomarker analysis. The team recorded the intercontinental shipment as taking around eighteen and a half days.

Nothing in that account is improper. The consent was in place, the collaboration was genuine, the Nigerian institution did substantial work. But notice where the division falls. Nigeria did the recruitment, the collection, the extraction and the storage. The sequencing, which is where the data is created and where the capability compounds, happened four thousand miles away.

That division is the subject of this piece.

The historical version has a name

Researchers call it helicopter research, or parachute science. Samples collected in Africa, shipped to laboratories in high-income countries, with no local oversight of what happened to them afterwards. One review of genomic biobank governance in Africa describes it as the starkest example of exploitation in the field's history, and identifies the specific loss: African researchers were deprived of a resource that could have built local scientific capacity and answered locally relevant questions.

Prof. Fatumo, a Nigerian genomicist, has described the earlier era of African genomic study in blunt terms, citing ethical dumping and exploitation, samples gathered with little regard for consent and nothing returned to the communities studied.

That is history, and a good deal has changed. H3Africa, the continental genomics initiative, trained 137 PhDs and 49 postdoctoral researchers along with hundreds of masters and undergraduate students. Several of Nigeria's leading genomics figures came through it. African researchers now conduct a substantial and growing share of African genomic research.

The Journey of One Sample

Nigeria did the recruitment, the collection, the extraction and the storage. The sequencing, which is where the data is created and where the capability compounds, happened somewhere else.

1. 01Collection sites across West AfricaBlood drawn, consent taken, participants recruited.
2. 02Coordinating centre, IbadanDNA extraction, plasma isolation and long-term storage.

   Leaves Nigerian jurisdiction

3. 03University institute, MiamiWhole genome sequencing and biomarker analysis, around four thousand miles away. The team recorded the intercontinental shipment as taking around eighteen and a half days.

What comes back

A result.

What stays at the destination

The primary output, the processing pipeline, and the operational knowledge of running it. The capability stays where the sequencer is.

What the arrangement costs

Three things leave with the sample.

The data is created abroad. Sequencing is not a service performed on a sample and returned. It is the point at which the sample becomes data, and the institution that performs it holds the primary output, the processing pipeline, and the operational knowledge of running it. The sample goes out. A result comes back. The capability stays where the sequencer is.

The reference data never accumulates. Africa remains at under two percent representation among human genomes analysed to date, despite African populations carrying the highest genetic variation in the world. Each study that ships its samples out contributes to a foreign dataset rather than a domestic one. There is no national allele frequency resource because no institution has been positioned to accumulate one.

The commercial value is realised elsewhere. Therapeutics developed on those datasets are sold back into the markets that supplied the samples. This is the point NBRDA's Director-General made on national television: the drugs imported into Nigeria were not developed on the basis of analysis of Nigerian or African genomes.

The rule that would change it already exists elsewhere

Uganda's national ethics guidelines take a position Nigeria has not. Under them, biological samples may be exported only after it has been demonstrated that in-country capacity to perform the required analysis does not exist or is inadequate. Export for quality control and reference purposes is separately permitted. Transfers require clearance from the national science council and a material transfer agreement.

That is a capacity-first rule rather than a prohibition. It permits export precisely when domestic capability is absent, which means it creates a standing incentive to build the capability, because building it changes what is permitted.

Nigeria's framework is thinner. The Nigeria Data Protection Act 2023 governs the movement of personal data out of the country under Part VIII, and applies to genomic data as sensitive personal data. But the physical movement of biological samples sits in a different regime, and the question of whether domestic capacity exists is not a gating condition anywhere in it.

What actually has to be built

Reversing the arrangement is not a matter of buying a sequencer. Four things have to exist together, and the absence of any one of them sends the samples abroad again.

Sequencing capacity with sustained throughput. An instrument that runs intermittently produces worse data at higher unit cost than a facility abroad running continuously. The constraint is reagent supply chains, trained operators and consistent sample volume, not the capital purchase.

Storage at the right scale, domestically. A single genome at thirty-fold coverage produces on the order of a hundred gigabytes of raw data. Ten thousand genomes approaches a petabyte. NBRDA has confirmed it is in discussion with Galaxy Backbone about hosting a national genomic data facility in Nigeria. That is the correct shape of answer.

Bioinformatics capability, which is the harder half. Producing reads is mechanical. Turning them into interpretable variant calls requires alignment, joint genotyping, quality control for contamination and ancestry, and annotation against reference databases that, as we have written elsewhere, do not describe Nigerian populations well. This is the part that cannot be bought.

Governance that makes domestic hosting worth trusting. Researchers will route around infrastructure they do not trust. Consent that can be withdrawn and have the withdrawal propagate, access controlled by a functioning data access committee, audit logging, and interoperability with the standards international collaborators already use.

The Domestic Sequencing Stack

Reversing the arrangement is not a matter of buying a sequencer. Four things have to exist together, and the absence of any one of them sends the samples abroad again.

ASequencing capacity with sustained throughputAn instrument that runs intermittently produces worse data at higher unit cost than a facility abroad running continuously. The constraint is reagent supply chains, trained operators and consistent sample volume, not the capital purchase.

BStorage at the right scale, domesticallyA single genome at thirty-fold coverage produces on the order of a hundred gigabytes of raw data. Ten thousand genomes approaches a petabyte.

CBioinformatics capability, which is the harder halfAlignment, joint genotyping, quality control for contamination and ancestry, and annotation against reference databases that do not describe Nigerian populations well. This is the part that cannot be bought.

DGovernance that makes domestic hosting worth trustingConsent that can be withdrawn and have the withdrawal propagate, access controlled by a functioning data access committee, audit logging, and interoperability with the standards international collaborators already use.

The point

The argument for domestic capability is not that international collaboration is undesirable. Collaboration is how the field works, and the Uganda rule explicitly preserves export where it is warranted.

The argument is narrower. Where the sequencing happens determines where the capability accumulates, where the reference data lives, and who is in a position to answer the next question. Nigeria has been supplying the input to that process for a long time without ever holding the machinery.